GENASENSE Trademark

Trademark Overview

On Friday, April 28, 2000, a trademark application was filed for GENASENSE with the United States Patent and Trademark Office. The USPTO has given the GENASENSE trademark a serial number of 76036889. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 19, 2014. This trademark is owned by GENTA INCORPORATED. The GENASENSE trademark is filed in the Pharmaceutical Products category with the following description:

Oligonucleotide pharmaceutical preparations for the treatment of cancer and rheumatological diseases
genasense

General Information

Serial Number76036889
Word MarkGENASENSE
Filing DateFriday, April 28, 2000
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 19, 2014
Registration Number2843372
Registration DateTuesday, May 18, 2004
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 18, 2001

Trademark Statements

Goods and ServicesOligonucleotide pharmaceutical preparations for the treatment of cancer and rheumatological diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 19, 2014
Primary Code005
First Use Anywhere DateThursday, November 1, 2001
First Use In Commerce DateThursday, November 1, 2001

Trademark Owner History

Party NameGENTA INCORPORATED
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBerkeley Heights, NJ 07922
Party NameGENTA INCORPORATED
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421
Party NameGENTA INCORPORATED
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events

Event DateEvent Description
Friday, December 19, 2014CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Monday, August 9, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 3, 2010REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, June 3, 2010CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, May 18, 2010TEAS SECTION 8 & 15 RECEIVED
Tuesday, July 8, 2008APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 8, 2008TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, May 20, 2008ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 20, 2008TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, May 18, 2004REGISTERED-PRINCIPAL REGISTER
Tuesday, March 9, 2004ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, February 18, 2004NON-FINAL ACTION MAILED
Friday, January 16, 2004CASE FILE IN TICRS
Friday, January 16, 2004ASSIGNED TO EXAMINER
Wednesday, January 14, 2004CASE FILE IN TICRS
Monday, January 12, 2004ASSIGNED TO EXAMINER
Saturday, January 10, 2004STATEMENT OF USE PROCESSING COMPLETE
Wednesday, December 17, 2003USE AMENDMENT FILED
Wednesday, December 17, 2003TEAS STATEMENT OF USE RECEIVED
Tuesday, October 14, 2003PAPER RECEIVED
Tuesday, June 17, 2003NOA MAILED - SOU REQUIRED FROM APPLICANT
Sunday, December 8, 2002OPPOSITION TERMINATED NO. 999999
Sunday, December 8, 2002OPPOSITION DISMISSED NO. 999999
Tuesday, June 18, 2002OPPOSITION INSTITUTED NO. 999999
Monday, April 15, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 15, 2002PAPER RECEIVED
Tuesday, January 22, 2002EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, December 18, 2001PUBLISHED FOR OPPOSITION
Wednesday, November 28, 2001NOTICE OF PUBLICATION
Wednesday, August 1, 2001APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 27, 2001EXAMINERS AMENDMENT MAILED
Monday, March 26, 2001CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 24, 2000NON-FINAL ACTION MAILED
Friday, October 20, 2000ASSIGNED TO EXAMINER
Friday, September 22, 2000ASSIGNED TO EXAMINER

Related Keywords

genasense rheumatological diseases cancer treatment pharmaceutical preparations oligonucleotide